Compare ADMA Biologics Inc (ADMA) vs Nebius Group NV (NBIS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Nebius Group NV — how do they compare? ADMA Biologics Inc trades at $9.23 (market cap $2.13B), while Nebius Group NV trades at $205 (market cap $49.56B). The key difference: Nebius Group NV is far larger — about 23.3× ADMA Biologics Inc's market cap, and Nebius Group NV is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | NBIS | |
|---|---|---|
Market Cap | $2.13B | $49.56B |
Sector | Health | Technology |
52-Week High | $20.38 | $286.69 |
52-Week Low | $7.60 | $44.30 |
Enterprise Value | $2.20B | $49.76B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
NBIS trades at $213.02, down 1.21% with bearish technical signals despite strong analyst support. The stock shows premium valuations (P/E 82.25, P/S 64.41) but impressive profitability (93.09% net margin) and robust revenue growth projections from $530M to $878M. Recent volatility stems from Meta's potential cloud competition, though news highlights Nebius's AI infrastructure strength and institutional buying interest.
Outlook remains positive with 87.5% analyst buy ratings and $233.13 consensus target, but high valuation and competitive risks from tech giants temper near-term upside. Cash flow trends show aggressive expansion funding, while earnings beats/misses reflect execution volatility in a high-growth sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Nebius Group NV
Nebius Group N.V. is a technology company specializing in AI, machine learning, and cloud computing solutions. The company provides a range of enterprise-level cloud services, including large-scale data processing, advanced analytics, and AI model development and deployment. Nebius Group focuses on serving businesses that require high-performance, scalable, and secure infrastructure to handle complex computational tasks and accelerate their digital transformation.
Read more on NBIS →
